CN107530361A - 用于调节骨密度的方法 - Google Patents

用于调节骨密度的方法 Download PDF

Info

Publication number
CN107530361A
CN107530361A CN201680022614.7A CN201680022614A CN107530361A CN 107530361 A CN107530361 A CN 107530361A CN 201680022614 A CN201680022614 A CN 201680022614A CN 107530361 A CN107530361 A CN 107530361A
Authority
CN
China
Prior art keywords
disease
compound
subject
hydrogen
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680022614.7A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·夏皮罗
阿多里尼·卢西亚诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ntercept Pharmaceuticals Inc
Original Assignee
Ntercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ntercept Pharmaceuticals Inc filed Critical Ntercept Pharmaceuticals Inc
Publication of CN107530361A publication Critical patent/CN107530361A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680022614.7A 2015-03-09 2016-03-08 用于调节骨密度的方法 Pending CN107530361A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130144P 2015-03-09 2015-03-09
US62/130,144 2015-03-09
PCT/US2016/021344 WO2016144946A1 (en) 2015-03-09 2016-03-08 Methods for modulating bone density

Publications (1)

Publication Number Publication Date
CN107530361A true CN107530361A (zh) 2018-01-02

Family

ID=56879295

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680022614.7A Pending CN107530361A (zh) 2015-03-09 2016-03-08 用于调节骨密度的方法

Country Status (12)

Country Link
US (1) US20180042943A1 (https=)
EP (1) EP3268009A4 (https=)
JP (1) JP2018507880A (https=)
KR (1) KR20170125927A (https=)
CN (1) CN107530361A (https=)
AU (1) AU2016229906A1 (https=)
CA (1) CA2978916A1 (https=)
HK (1) HK1243646A1 (https=)
IL (1) IL254197A0 (https=)
MX (1) MX2017011399A (https=)
SG (1) SG11201707328SA (https=)
WO (1) WO2016144946A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US10919162B2 (en) 2018-12-26 2021-02-16 Ford Global Technologies, Llc Systems and methods for efficient power management of modular mobile robot platforms with replaceable batteries
DE102020101118A1 (de) 2019-01-18 2020-07-23 Ford Global Technologies, Llc Mobile mehrzweckroboter und verfahren zu deren verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223214B2 (en) * 2002-03-01 2008-09-18 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003080803A2 (en) * 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
JP2012072095A (ja) * 2010-09-29 2012-04-12 Tokyo Institute Of Technology 骨形成促進剤
NZ734451A (en) * 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
WO2014021694A1 (ko) * 2012-08-03 2014-02-06 서울대학교 산학협력단 골 관련 질환 예방 및 치료를 위한 조성물
CA2912139C (en) * 2013-05-14 2021-04-20 Roberto Pellicciari 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SIMON HOHENESTER等: "Primary biliary cirrhosis", 《SEMIN IMMUNOPATHOL》 *
SUN WOOK CHO等: "Positive Regulation of Osteogenesis by Bile Acid Through FXR", 《JOURNAL OF BONE AND MINERAL RESEARCH》 *

Also Published As

Publication number Publication date
JP2018507880A (ja) 2018-03-22
KR20170125927A (ko) 2017-11-15
EP3268009A1 (en) 2018-01-17
HK1243646A1 (zh) 2018-07-20
CA2978916A1 (en) 2016-09-15
IL254197A0 (en) 2017-10-31
US20180042943A1 (en) 2018-02-15
WO2016144946A1 (en) 2016-09-15
AU2016229906A1 (en) 2017-09-21
MX2017011399A (es) 2018-03-16
SG11201707328SA (en) 2017-10-30
EP3268009A4 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
Yan et al. Oryzanol alleviates high fat and cholesterol diet-induced hypercholesterolemia associated with the modulation of the gut microbiota in hamsters
CN107405325B (zh) 用于组合疗法的药物组合物
US6426340B1 (en) Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-FUDCA)
EP3842043A1 (en) Methods for using fxr agonists
US20160354387A1 (en) Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof
US20230138455A1 (en) METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs)
WO2023081370A1 (en) Treatment with ileal bile acid transporter (ibat) inhibitors for increased event-free survival (efs)
CN107530361A (zh) 用于调节骨密度的方法
EA014077B1 (ru) Применение 24-нор-урсодеоксихолевой кислоты
CA2721728A1 (en) Treatment of inflammatory bowel disease with 6-mercaptopurine
US20190365697A1 (en) Method for Treating Liver Dysfunction
WO2019004465A1 (ja) ペマフィブラートを含有する医薬
WO2022237731A1 (zh) 一种治疗高脂血症的药物组合物及其制备方法
WO2020240483A1 (en) Combination of a polyhydroxylated bile acid and a farnesoid x receptor agonist
US20240100001A1 (en) Denatonium salt for use in preventing, preventing progression and treating fatty liver diseases
US20170071968A1 (en) Pharmaceutical composition based on a hepatoprotector and prebiotic, and method for administrating
JP2616845B2 (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
EP4225291B1 (en) Treatment of cholangiopathies with seladelpar
TWI612959B (zh) 含有亞鐵胺基酸螯合物之組合物用於製造治療肝功能異常之醫藥品的用途
JP2002114672A (ja) Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤
TWI228992B (en) Treatment of subnormal bone mineral density
HK40092040B (en) Treatment of cholangiopathies with seladelpar
HK40110368B (en) Phenyl pyrrole aminoguanidine salts and formulations
van Vliet et al. Renger G. Tiessen1, Ciara A. Kennedy2, Bradley T. Keller2, Nancy Levin2, Lisette Acevedo2, Bronislava Gedulin2
Mayo Non-PBC, Non-PSC autoimmune cholangiopathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1243646

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180102

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1243646

Country of ref document: HK